Healthcare professionals only
This section is intended for qualified doctors, pharmacists and other
authorised healthcare professionals.
Go to Professional Resources →
Scientific & Prescribing Resources
HonniHil® information for healthcare professionals
Professional product, prescribing, safety and medical-information resources relating to HonniHil® tadalafil 20 mg tablets.
This page provides a structured professional overview. The current locally approved prescribing information remains the controlling source for indication, dosage, contraindications, warnings and adverse reactions.
Product at a glance
Core HonniHil® product information
These details should be checked against the current approved pack, product dossier and NAFDAC documentation before publication.
Approved indication
Management of erectile dysfunction
HonniHil® contains tadalafil and is intended for use in adult men with erectile dysfunction under the direction of a qualified prescriber.
Regulatory control:
Use the exact indication wording in the current NAFDAC-approved
prescribing information. Do not extend the indication to premature
ejaculation, relationship outcomes or unapproved patient groups.
Mechanism summary
Tadalafil selectively inhibits phosphodiesterase type 5. During sexual stimulation, PDE5 inhibition increases cGMP-mediated smooth muscle relaxation and supports increased penile blood flow.
View the full mechanism page →
Prescribing overview
Use the current approved prescribing information
Dosage and administration may depend on indication, renal or hepatic function, concomitant medicines and individual tolerability. The website should not replace the approved local prescribing document.
Dosage and administration
Display the exact authorised dose, timing, maximum frequency and food instructions from the current HonniHil® prescribing information.
Renal and hepatic impairment
Confirm whether dose adjustment, reduced frequency or avoidance is required for specific degrees of renal or hepatic impairment.
Special populations
Use approved recommendations for older adults, patients with cardiovascular disease and populations not included in the indication.
Concomitant therapy
Review alpha blockers, antihypertensives, CYP3A4 inhibitors or inducers and other erectile-dysfunction treatments before prescribing.
Do not publish dosing from a generic tadalafil label
The dose shown on the HonniHil® pack does not by itself define the complete dosing instruction. Use the current locally approved document.
Contraindications and precautions
Key safety areas for professional review
This is a high-level summary only. Refer to the approved SmPC or prescribing information for complete wording and clinical decision-making.
Organic nitrates
Tadalafil is contraindicated with organic nitrates because it can potentiate their hypotensive effect.
Guanylate cyclase stimulators
Concomitant use with medicines such as riociguat may increase hypotensive effects and is contraindicated in reference labels.
Cardiovascular status
Assess whether sexual activity and PDE5-inhibitor treatment are appropriate for the patient’s cardiovascular condition.
Hypotension
Consider additive blood-pressure effects with alpha blockers, antihypertensives and substantial alcohol intake.
Priapism and penile conditions
Use caution in patients predisposed to prolonged erection or with anatomical penile conditions.
Vision and hearing events
Counsel patients on urgent assessment for sudden vision or hearing changes.
Renal and hepatic function
Apply the approved dose limitations and monitoring recommendations.
Hypersensitivity
Do not prescribe to patients with serious hypersensitivity to tadalafil or another ingredient.
Clinically relevant interactions
Review the complete medicine list
Consider prescription medicines, non-prescription products, supplements, alcohol and recreational substances.
Medicine or factor
Professional consideration
Organic nitrates
Contraindicated because of potentially severe hypotension.
Riociguat or other GC stimulators
Contraindicated in reference tadalafil labels.
Alpha blockers
Potential additive hypotension; review stability, dose and timing.
Antihypertensives
Monitor for additive blood-pressure reduction where clinically appropriate.
Potent CYP3A4 inhibitors
May increase tadalafil exposure; apply the approved dosing limitation.
CYP3A4 inducers
May reduce tadalafil exposure and therapeutic response.
Other PDE5 inhibitors or ED treatments
Combination safety and efficacy are not established; avoid unapproved combination use.
Substantial alcohol intake
May increase orthostatic symptoms, dizziness or hypotension.
Adverse reactions
Use approved frequency categories
Tadalafil reference labels commonly describe headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and pain in the limbs.
Do not publish a frequency table until the categories and percentages have been checked against the current HonniHil® prescribing information.
Events requiring urgent assessment or discontinuation advice
- Priapism or an erection lasting longer than four hours.
- Sudden vision loss or significant visual change.
- Sudden hearing loss or severe auditory symptoms.
- Severe hypersensitivity reaction.
- Chest pain, syncope or serious cardiovascular symptoms.
Professional resources
Approved product documents and materials
Publish only current, approved and version-controlled materials. Remove superseded brochures and legacy claim-led content.
Prescribing Information
Current professional product information
Download →
Patient Information Leaflet
Approved patient-facing medicine information
Download →
Approved Product Literature
Current NAFDAC-approved professional materials
Download →
Approved Product Images
Current pack and blister image assets
Download →
Medical and safety support
Direct professional enquiries to the right team
Separate medical-information requests, adverse-event reports and product-quality complaints. They require different review and follow-up processes.
Professional information notice: This page is a structured website draft and does not replace the current NAFDAC-approved prescribing information, SmPC, product dossier or clinical judgement.